fr | en
Micro et Nanomédecines translationnelles

Separated by coma

Coordinator : Dr Guillaume BASTIAT

GLIOGEL : Prevention of GLIOblastoma recurrence by injection in the resection cavity of a hydroGEL formed by targeted lipid nanocapsules loaded with anticancer drugs


Despite their low prevalence (annual global incidence of 5 cases out of 100,000 in the European Union and United States), Glioblastoma (GBM), that is malignant brain tumours, result in high morbidity and mortality. Due to recurrences from infiltrating GBM cells at the border of resection, the median survival is 14 months with the current standard of care (surgical resection combined with adjuvant radiotherapy and/or chemotherapy). The objective of this research project is to develop an implantable hydrogel technology which will bridge the current therapeutic needs between surgical resection and initiation of systemic regimens.

In this project, a polymer-free hydrogel prepared from biodegradable lipid nanocapsules (LNCs) will act as a sustained-release matrix to deliver targeted therapeutic nanoparticles specifically to cancer cells. This technology is expected to limit GBM recurrences by i) maintaining therapeutic concentrations of anticancer drugs at the resection border (without the necessity of crossing the blood-brain barrier) and ii) targeting GBM cells specifically using a unique proprietary targeting peptide (NFL-TBS.40-63) (NFL). 

Our preliminary data shows that the peptide NFL can adsorb at the surface of LNCs. This surface functionalization can be used to target drug-loaded LNCs to GBM cells in vivo, and achieve therapeutic efficacy. In parallel, when using a crosslinking agent, LNCs can self-associate in a network forming a polymer-free hydrogel. When loaded with drugs, this hydrogel can provide sustained release and improve in vivo therapeutic efficacy compared to the drug alone. The GLIOGEL project will combine these two independent technologies to create unique synergy.

The translational multidisciplinary proposal will bridge nanotechnology, chemical engineering, pharmaceutical sciences and neuro-oncology research to address an existing clinical need. The use of innocuous materials and excipients, as well as easily scalable manufacturing processes will ensure the prototypes achieve high technology readiness levels while meeting all clinically-relevant requirements.


Guillaume Bastiat (Coordinator)

MINT - INSERM U1066/CNRS UMR 6021, Université d’Angers


4 Rue Larrey

49933, Angers cedex 9, France


Véronique Préat

Louvain Drug Research Institute, Université Catholique de Louvain

Avenue E. Mounier, 73 bte B1.73.12

1200, Brussels, Belgium


Nicolas Bertrand

Faculty of Pharmacy/CHU de Quebec Research Center, Université Laval

2705 Boul. Laurier

Québec (QC), G1V 4G2, Canada


Claire Lépinoux-Chambaud



4 Rue Larrey

49933, Angers cedex 9, France